Executive Summary
Two simultaneous shocks reshaped the aortic stenosis landscape today: JACC published 10-year PARTNER 2A data showing higher mortality (86.1% vs 82.8%, HR 1.13) and a near 4-fold higher reintervention rate (6.3% vs 1.6%) with the second-generation Sapien XT valve versus surgery in intermediate-risk patients, while a matched comparison using the third-generation Sapien 3 erased that mortality gap (83.4% vs 82.3%). Hours earlier, CMS proposed extending Medicare TAVR coverage to asymptomatic severe AS and dropping CED requirements for symptomatic cases, and the PREVUE-VALVE population study in JACC estimated 10.6 million older Americans currently have clinically significant valvular disease. Together these tighten the case for TAVR generation-specific durability claims while loosening the gatekeeping around who gets one — and the surgical community has reason to push back on both fronts.
- PARTNER 2A 10-year mortality penalty for TAVR was driven entirely by the transthoracic access subgroup (93.2% vs 85.1%, P<0.01); transfemoral TAVR matched surgery (JACC).
- Moderate-or-greater paravalvular regurgitation at 10 years was 10.5% with Sapien XT versus 0% with surgery — a durability signal that won't disappear with valve generation alone (TCTMD on JACC).
- French nationwide cohort (n=255,453) found TAVR uptake rose tenfold from 2010-2022, but neither PARTNER trials nor ESC guideline updates produced statistically detectable inflection points (p≥0.125) (PLoS One).
- Edwards stock hit a 52-week high of $89.60 on the CMS proposal, closing +2.67%, with Leerink reiterating its rating on the policy tailwind (Investing.com).
- A meta-analysis of 53 studies (n=157,921) found balloon-expandable valves cut early mortality and pacemaker rates while self-expanding valves delivered better hemodynamics — no winner long-term (J Cardiol).
What to watch: The CMS final decision memo is due in September; the 30-day public comment window will surface whether AATS, STS, and ACC dig in on the asymptomatic indication and CED retention.
Aortic Valve (TAVR/TAVI)
The 10-year PARTNER 2 data complicate the TAVR-equivalence narrative more than the headlines suggest. In PARTNER 2A (JACC), Sapien XT TAVR carried a 10-year mortality HR of 1.13 versus surgery and a 6.3% versus 1.6% reintervention rate, with moderate-or-greater paravalvular regurgitation at 10.5% versus 0%. The matched Sapien 3 comparison from P2S3i (JACC) showed equivalence on mortality and reintervention — but P2S3i was a registry propensity-matched against PARTNER 2A surgical patients, not a randomized comparison, and 10-year echo data existed for only 24-32 patients per arm. [NOTABLE] The surgical counterpoint matters: Borger's accompanying editorial notes structural valve deterioration rises exponentially in surgical bioprostheses between years 5 and 10, and these intermediate-risk PARTNER cohorts averaged 82 years — too old to fully stress test durability. ACC/AHA 2020 still favors SAVR under 65; the new data don't change that calculus. Separately, a 53-study meta-analysis (J Cardiol) reported balloon-expandable valves reduced 1-month mortality (RR 0.75) and pacemaker rates (RR 0.75) versus self-expanding, with self-expanding valves showing 3-8 mmHg lower mean gradients. A 2-year Chinese registry (n=163, 46.6% bicuspid) of the VitaFlow Liberty reported 13.5% mortality and 19.5% pacemaker rates — single-arm, no comparator, and a pacemaker rate that should give pause.
Mitral Valve (MitraClip, PASCAL, TMVR)
No primary mitral trials today, but PREVUE-VALVE in JACC quantifies the addressable population in a way the field has lacked: among 3,000 randomly selected Americans aged 65-85 who completed in-home echo, mitral regurgitation was the third most common moderate-or-greater lesion, behind tricuspid regurgitation and aortic stenosis. Weighted national prevalence of clinically significant valvular disease reached 18.4%, projecting to 14.7 million Americans by 2060. The decentralized methodology — randomized pharmacy outreach, home echo — is itself a study design worth flagging. Per ESC 2025, TEER for ventricular secondary MR is Class I; ACC/AHA 2020 still holds at Class IIa. Today's PREVUE-VALVE data don't adjudicate that disagreement but they expand the denominator dramatically.
Tricuspid Valve (TriClip, TTVR)
Tricuspid regurgitation was the single most prevalent valve lesion in PREVUE-VALVE (JACC), outranking aortic stenosis in older Americans. This sits squarely on top of the ESC 2025 Class IIa recommendation for transcatheter TR treatment in high-risk symptomatic patients — a recommendation that has no ACC/AHA equivalent. The U.S. guideline gap and the prevalence data together make TR the most under-treated lesion in structural heart, and the commercial implication for Edwards EVOQUE and Abbott TriClip is now backed by population-scale denominators rather than registry extrapolation.
Surgical vs. Transcatheter Comparisons
The PARTNER 2 dual analysis is the head-to-head of the day. The honest read: Capodanno's JACC editorial frames it as long-term data meeting a long-standing debate, and the field should resist the urge to treat the Sapien 3 matched analysis as randomized evidence of durability equivalence. A propensity-matched registry comparison run against a trial control arm is hypothesis-generating, not confirmatory. An Israeli single-payer cohort separately reported 44% 3-year mortality in TAVR nonagenarians versus 26% in 80-89 year-olds (P<0.01) — small (n=36), but a reminder that TAVR feasibility and TAVR benefit are different questions. The PARTNER 3 and Evolut Low Risk 10-year readouts remain the trials that will actually settle low-risk durability.
Device & Technology
A preclinical paper in J Materials Chem B describes metal-phenolic network coatings with EGCG and copper on glutaraldehyde-crosslinked leaflets achieving 90% reduction in calcium deposition and 50% improvement in endothelial proliferation versus controls. Bench and rodent data only — but the anti-calcification and pro-endothelialization story addresses precisely the failure mode that PARTNER 2A 10-year data just put back in the spotlight. Anteris publicly positioned its DurAVR as the next-generation answer to durability concerns — investor pitch language, but the underlying clinical question is real.
Regulatory & Policy
[NOTABLE] CMS proposed three substantive changes to the TAVR NCD: Medicare coverage for asymptomatic severe AS, removal of CED requirements for symptomatic cases, and streamlined facility volume and procedural assessment requirements. CMS explicitly preserved the multidisciplinary heart team — surgeons stay at the table. The asymptomatic expansion is built on EARLY TAVR (NEJM, 2024) and aligns with ESC 2025 Class IIa for early intervention in low-risk asymptomatic severe AS; ACC/AHA 2020 reserves early intervention for very severe AS, elevated BNP, or abnormal exercise testing. The five U.S. societies (AATS, ACC, HFSA, SCAI, STS) jointly opposed CED removal in January. Expect that fight to reopen in the 30-day comment window. Gupta's JACC editorial raises the right question: which valve, which patient, which era. The policy is moving faster than the answer.
Industry & Market
Edwards is the clear winner of the CMS proposal — its Sapien 3 family is the only TAVR platform FDA-approved for asymptomatic severe AS (granted May 2025), giving it first-mover advantage on the expanded indication. Medtronic and Abbott benefit secondarily from the dropped CED burden. MassDevice notes all three of Edwards, Medtronic, and Abbott stand to benefit from facility volume threshold flexibility expanding the addressable hospital footprint.
Financial Analysis
The market response disentangled the clinical story from the policy story neatly. Edwards rallied 2.67% on CMS, hitting a fresh 52-week high — pricing in volume expansion from the asymptomatic indication regardless of what 10-year PARTNER 2A showed. The PARTNER 2A Sapien XT mortality penalty is a sunk cost: that valve is no longer in commercial use. The Sapien 3 matched analysis was the data investors needed to keep the durability narrative intact for the currently shipping platform. The unresolved exposure is what PARTNER 3 5- and 7-year data will show in low-risk, younger patients where structural valve deterioration is biologically more likely to surface. The French registry finding that neither trials nor guidelines moved national TAVR adoption rates statistically should temper any modeling assumption that CMS expansion automatically translates to a step-change in volumes — TAVR growth has been driven by infrastructure and operator capacity, not coverage policy alone.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $88.58, +2.67% on the day, hitting a 52-week high of $89.60
- 6-month performance: +4.41%
- Market cap $51.0B, P/E trailing 47.88, forward P/E 26.3, beta 0.87
- Analyst consensus: buy, target $96.92 (range $84-$110, 26 analysts)
- Next earnings 2026-07-23 (EPS est $0.74, revenue est $1.70B)
Stock leadership today reflects pure policy tailwind: CMS asymptomatic expansion gives Edwards the only currently approved platform in a new indication, and Sapien 3 10-year data validates the platform in commercial use. The PARTNER 2A Sapien XT mortality finding doesn't impair current product.
Medtronic (MDT)
- Close $81.32, +1.17% on the day
- 6-month performance: -15.98%
- Market cap $104.4B, P/E trailing 21.57, forward P/E 12.69, beta 0.6
- Analyst consensus: buy, target $98.00 (range $78-$121, 26 analysts)
- Next earnings 2026-08-18 (EPS est $1.39, revenue est $9.55B)
Evolut platform benefits from CED removal but Medtronic has no asymptomatic approval — Evolut Low Risk long-term data is the next material catalyst. 6-month underperformance reflects broader portfolio concerns, not structural heart specifically.
Abbott (ABT)
- Close $90.62, +2.20% on the day
- 6-month performance: -27.67%
- Market cap $157.8B, P/E trailing 25.38, forward P/E 14.96, beta 0.62
- Analyst consensus: buy, target $116.54 (range $92-$135, 24 analysts)
- Next earnings 2026-07-16 (EPS est $1.28, revenue est $12.53B)
Abbott's structural heart exposure is mitral (MitraClip) and tricuspid (TriClip) — today's PREVUE-VALVE prevalence data (TR most common lesion) is the underappreciated tailwind. ESC 2025 Class IIa for transcatheter TR is the regulatory framework Abbott needs ACC/AHA to converge on.
Boston Scientific (BSX)
- Close $46.92, +0.34% on the day
- 6-month performance: -50.34%
- Market cap $69.7B, P/E trailing 19.63, forward P/E 12.6, beta 0.56
- Analyst consensus: strong buy, target $77.10 (range $55-$106, 30 analysts)
- Next earnings 2026-07-29 (EPS est $0.83, revenue est $5.38B)
Sharp 6-month drawdown disconnects from analyst sentiment — strong buy consensus and a target implying significant upside suggest the market is pricing in something the sell side isn't. ACURATE and Sentinel exposure remain core structural heart positions.
Anteris Technologies (AVR.AX)
- Close A$12.53, -7.19% on the day
- 6-month performance: +73.55%
- Market cap A$1.2B, forward P/E -5.75 (loss-making), beta 0.73
- Analyst coverage: 1 analyst, target A$13.00
Anteris explicitly positioned its DurAVR as the durability answer to TAVR's long-term failure modes — a narrative that 10-year PARTNER 2A data oxygenates. Pullback today against a 73% 6-month run suggests profit-taking on the news cycle rather than a thesis break.
Market outlook: today separated platform exposure from policy exposure. Edwards captured both. The structural heart sector now needs PARTNER 3 and Evolut Low Risk extended follow-up to validate the durability claim that current device pricing assumes. CMS expanded the demand side faster than the evidence resolved the supply-side durability question — a gap the next ACC/AHA guideline cycle will have to address.
Clinical Trial Updates
PARTNER 2A and P2S3i 10-year readouts dominate today's trial news. PARTNER 2A used FDA-mandated vital status sweeps to push completeness to ~90%, addressing the long-acknowledged attrition problem in long-duration valve trials — a methodological point worth noting for how PARTNER 3 will be evaluated. The pre-specified P2S3i propensity match against PARTNER 2A surgical controls is creative trial design but also a structural compromise: it's not the randomized comparison the field actually needs.
Social & Conference Highlights
The JACC dual publication will drive discussion at upcoming structural heart sessions. Capodanno, Borger, and Gupta editorials are required reading — Borger in particular brings the surgical lens that the durability conversation needs.
Forward look: the September CMS final decision memo, the public comment period response from cardiac surgery societies, and the next PARTNER 3 follow-up will together determine whether today's policy expansion is matched by durability evidence in the lower-risk, younger population where the question actually matters.
— E. Nolan Beckett, MD